Business
Vector Science & Therapeutics Enters Three-Year Development and Manufacturing Agreement with MPP Group LLC
Vector Science & Therapeutics Enters Three-Year Development and Manufacturing Agreement with ...
About this update from Vector Science And Therapeutics Corp.
[{"type":"text","content":"\n\n\nVector Science & Therapeutics Enters Three-Year Development and Manufacturing Agreement with MPP Group LLC\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nPADDING-RIGHT:0.17em; PADDING-LEFT:0.17em; VERTICAL-ALIGN: TOP; BORDER-TOP:black 0.5pt solid; BORDER-RIGHT:black 0.5pt solid; BORDER-BOTTOM:black 0.5pt solid; BORDER-LEFT:black 0.5pt solid\n}\n.prngen3{\nPADDING-RIGHT:0.17em; PADDING-LEFT:0.17em; VERTICAL-ALIGN: MIDDLE; BORDER-TOP:black 0.5pt solid; BORDER-RIGHT:black 0.5pt solid; BORDER-BOTTOM:black 0.5pt solid; BORDER-LEFT:black 0.5pt solid\n}\n.prnml4{\nMARGIN-TOP:0em; MARGIN-RIGHT:0em; MARGIN-BOTTOM:0em; MARGIN-LEFT:0.33em !IMPORTANT\n}\n.prnml40{\nMARGIN-LEFT:3.33em !IMPORTANT\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\nVector Science & Therapeutics Enters Three-Year Development and Manufacturing Agreement with MPP Group LLC\nCanada NewsWire\n\n\nAgreement provides Vector access to FDA-registered, cGMP facility and supports development of 24 novel shelf-stable peptide formulations targeting the $80.8 billion peptide marketMEQUON, Wis., May 11, 2026 /CNW/ -- Vector Science & Therapeutics (TSXV: PAIN) (\"Vector\" or the \"Company\") today announced that it has entered into a development and manufacturing agreement with MPP Group LLC (\"MPP\"), a Mequon, Wisconsin-based contract development and manufacturing organization, to develop and manufacture pharmaceutical-grade peptides and to manufacture drug delivery devices developed by Vector.\n\n\n\n\n\n\n\nThe three-year agreement co-locates compound formulation, analytical testing, and Vector's proprietary transdermal delivery platform within a single FDA-registered, cGMP-compliant facility, accelerating development cycles and ensuring quality from formulation through delivery. The arrangement supports the Company's entry into the $80.8 billion peptide market with pharmaceutical-grade, shelf-stable formulations.Key HighlightsFDA-registered, cGMP facility access: MPP's Mequon, Wisconsin facility represents approximately $6 million in capital expenditure that Ve...